NASADAD

Search
Skip to content
  • Login
  • Home
  • About Us
    • About Us
    • Board of Directors
    • NASADAD Staff
  • Contact Us
  • Mobile Menus
Public View

Buprenorphine Patient Limits: History and Overview

Image January 30, 2019 SWickramatilake

Download (PDF, 341KB)

Post navigation

Previous PostComments to CMS on Medicare Payment for Certain Services Furnished by Opioid Treatment ProgramsNext PostNASADAD releases overview of buprenorphine patient limits

Sign Up for Our Weekly Newsletter

Select list(s) to subscribe to

By submitting this form, you are consenting to receive marketing emails from: NASADAD, 1919 Pennsylvania Avenue NW, Washington, DC, 20006, http://www.nasadad.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
  • Our Members
    • Role of State Alcohol and Drug Agencies
  • NASADAD Annual Meeting
  • Public Policy
    • Substance Use Prevention, Treatment and Recovery Services (SUPTRS) Block Grant
    • NASADAD Fact Sheets
    • Legislative Summaries
    • Federal Budget and Appropriations
    • Letters & Regulatory Comments
    • NASADAD Presentations
    • D.C. Updates
    • Partnerships for Success Information
    • Hot Topics
    • State Specific Information
    • Health Reform Information
    • Members Only
  • Prevention
    • National Prevention Network
    • NPN Conference
    • Innovative Substance Abuse Prevention Programs, Practices and Policies
    • National Prevention Resources
  • Treatment & Recovery
    • National Treatment Network
    • Women’s Services Network
    • Opioid Treatment Network
    • HIV Coordinators
    • Youth Coordinators
    • State Treatment & Recovery Resources
  • Resources
    • NASADAD Reports
    • Federal Resources
    • NASADAD Component Groups
    • Research
  • Job Postings
  • Show Member Menus
© The National Association of State Alcohol and Drug Agency Directors